Abstract:Pirh2 is a Ring-H2 domain containing E3 ubiquitin ligase that targets several important tumor suppressor genes for proteasomal degradation. Overexpression of Pirh2 is frequently detected in many clinical tumor tissues including hepatocellular carcinoma (HCC). However, the molecular mechanism of Pirh2 activation in tumorigenesis still remains poorly understood. In this study, we find a Pirh2-binding protein, SCYL1 binding protein 1 (SCYL1BP1), that can promote the ubiquitin-dependent degradation of Pirh2. SCYL1BP1 colocalized with Pirh2 in the cytoplasm and prevented its localization to the nucleus. Ectopic expression of SCYL1BP1 increased the expression of p53 and further inhibited the G(1)/S transition of HCC cell lines. Conversely, knock down of SCYL1BP1 restored the expression of Pirh2 and inhibited p53 at protein level. Functional assays found that reintroduction of SCYL1BP1 into HCC cell lines significantly inhibited cell proliferation, foci formation, colony formation in soft agar and tumor formation in nude mice, suggesting the strong tumor-suppressive function of SCYL1BP1 in HCC progression. Furthermore, SCYL1BP1 was found to be frequently downregulated in HCC clinical specimens compared to their paired non-tumor tissues by immunohistochemical staining. Taken together, our data suggested that the interaction of SCYL1BP1/Pirh2 could accelerate Pirh2 degradation through an ubiquitin-dependent pathway. SCYL1BP1 may function as an important tumor suppressor gene in HCC development.

Pirh2 RING‐finger E3 Ubiquitin Ligase: Its Role in Tumorigenesis and Cancer Therapy

Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.

The E3 Ligase Ring1 Targets P53 For Degradation And Promotes Cancer Cell Proliferation And Survival

Pirh2 and Tumor

Research Progress in Association Between the Ubiquitin Ligase Pirh2 and Malignant Tumors

A Novel Oncoprotein Pirh2: Rising from the Shadow of MDM2.

Recent Insight into the Role of RING-finger E3 Ligases in Glioma

Figure S2 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Residues 240-250 in the C-Terminus of the Pirh2 Protein Complement the Function of the Ring Domain in Self-Ubiquitination of the Pirh2 Protein

Figure S5 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Figure S1 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

The P73 Tumor Suppressor is Targeted by Pirh2 RING Finger E3 Ubiquitin Ligase for the Proteasome-dependent Degradation*

Figure S4 from The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Figure S6 from the E3 Ligase RING1 Targets P53 for Degradation and Promotes Cancer Cell Proliferation and Survival

Identification of Pirh2E and Pirh2F, Two Additional Novel Isoforms of Pirh2 Ubiquitin Ligase from Human Hepatocellular Liver Carcinoma Cell Line

Phosphorylation of Pirh2 by Calmodulin-Dependent Kinase II Impairs Its Ability to Ubiquitinate P53.

SCYL1 Binding Protein 1 Promotes the Ubiquitin-Dependent Degradation of Pirh2 and Has Tumor-Suppressive Function in the Development of Hepatocellular Carcinoma

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

The Role and Therapeutic Implications of RING-finger E3 Ubiquitin Ligases in Hepatocellular Carcinoma

PIR promotes tumorigenesis of breast cancer by upregulating cell cycle activator E2F1